Bedossa P
Service d'Anatomie pathologique, Hôpital Beaujon, Clichy, France.
Gastroenterol Clin Biol. 2010 Sep;34 Suppl 2:S103-8. doi: 10.1016/S0399-8320(10)70028-2.
Liver fibrosis is a common complication of chronic hepatitis B leading to the progressive destruction of normal tissue architecture or the replacement of hepatocytic tissue with fibrous tissue. The final outcome of this process is liver cirrhosis, which is the major cause of morbidity and mortality in chronic viral hepatitis. Fibrogenesis is closely related to activation of the main type of fibrocompetent cells in the liver: hepatic stellate cells. Experimental models have allowed a better understanding of the dynamics of fibrosis, the biological processes related to its progression and regression and the development of new anti-fibrotic drugs. Nevertheless, it is universally accepted that such an anti-fibrotic treatment will be efficient only after hepatitis B virus eradication. Furthermore, early fibrosis is more amenable to regression than more advanced and highly organized liver cirrhosis.
肝纤维化是慢性乙型肝炎的常见并发症，会导致正常组织结构的渐进性破坏，或纤维组织取代肝细胞组织。这一过程的最终结果是肝硬化，而肝硬化是慢性病毒性肝炎发病和死亡的主要原因。肝纤维化的形成与肝脏中主要的纤维生成细胞——肝星状细胞的激活密切相关。实验模型有助于更好地理解纤维化的动态过程、与其进展和消退相关的生物学过程以及新型抗纤维化药物的研发。然而，人们普遍认为，只有在根除乙型肝炎病毒后，这种抗纤维化治疗才会有效。此外，早期纤维化比更晚期、组织更致密的肝硬化更易于消退。
